In summary, RUNX3 can inhibit the proliferation, migration, and invasion ability of human colorectal cancer HT-29, and its antineoplastic mechanism is through reducing the expression of MMP-2 and MMP-9, and ultimately inhibit the invasion and metastasis of colon cancer cells, but the pathway remains still unclear, which will also be our future research direction. This evidence concerns the gene MMP9 and colorectal cancer.